Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
← catalyst calendarNCT07187375 · readout in 1,114 d
Sponsored by Neurocrine Biosciences (industry) · NBIX — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
7actual
Sites
3
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | 2029-09-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-04 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Congenital Adrenal Hyperplasia
Intervention
- Drug: Crinecerfont
Primary outcome
what the primary-completion date above is the date OFPlasma Concentration of Crinecerfont
measured Days 7 and 15
Permalink · NBIX's whole pipeline · Catalyst calendar · Every registered study · What changed